C-Peptide - 1 Hour Response

Blood glucose can stay normal while your pancreas releases extra insulin to compensate for insulin resistance. A one-hour C-peptide measurement adds information about that response. It measures the concentration circulating 60 minutes into an oral glucose tolerance test, rather than the total insulin released during the first hour.

C-peptide testing is established in diabetes care, particularly when the amount of remaining insulin production or the diabetes diagnosis is uncertain. Using an isolated one-hour result to screen otherwise healthy people is less established. There is no universally accepted healthy or optimal target for this time point, and a single result cannot reliably distinguish insulin resistance from declining insulin production.

Why This Fragment Tracks Insulin Production

Beta cells are the pancreatic cells that make insulin. They first make a larger protein called proinsulin, which is cut to release insulin and C-peptide in equal numbers. The concentration of C-peptide in blood provides an indirect measure of insulin secretion.

C-peptide stays in the circulation longer than insulin and undergoes little removal by the liver. The kidneys play a major part in clearing it. Injected insulin contains no C-peptide, so it doesn't directly add to the measurement, although its effect on glucose can change how much insulin your pancreas releases.

This measurement uses serum from a venous blood draw taken one hour after the glucose drink. The laboratory measures C-peptide with an immunoassay. This method uses antibodies to detect the protein fragment.

The concentration reflects both release and clearance, as well as the glucose stimulus your pancreas received. It is not a direct count of surviving beta cells or a measurement of their maximum capacity. A fasting sample, a one-hour sample, and a series of samples across the glucose challenge answer different questions.

What the Type 1 Diabetes Studies Show

Some of the strongest evidence comes from relatives of people with type 1 diabetes who had islet autoantibodies. These antibodies recognize targets in pancreatic cells and are markers of an autoimmune process. Researchers followed glucose and C-peptide at several points during oral glucose tolerance tests to study progression toward clinical diabetes.

The timing of that downturn is not consistent across studies. A separate TrialNet analysis found no significant change in C-peptide until about six months before diagnosis.

A delayed response can occur when early insulin release is impaired and higher glucose continues to stimulate secretion later in the test. C-peptide can therefore remain substantial while the timing of the response changes. Identifying that pattern requires several timed samples; one sample at 60 minutes cannot establish when the peak occurred.

There is also evidence specifically supporting the one-hour measurement as part of a combined risk score. In autoantibody-positive cohorts, a score using fasting C-peptide, one-hour C-peptide and glucose, age, and body mass index predicted progression about as well as a score using the full two-hour test. A related and more widely used measure, Index60, combines fasting C-peptide with 60-minute C-peptide and glucose. These findings validate the combinations in this population, not one-hour C-peptide as a stand-alone screening test.

Insulin Resistance and a Larger Response

Insulin resistance means your tissues respond less strongly to insulin. Your pancreas may compensate by releasing more, which can produce a larger C-peptide response while glucose remains controlled. But the size of the response also depends on the glucose level, kidney function, age, and timing. A large one-hour response alone does not establish insulin resistance.

In a study comparing young people and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes, the younger group had larger insulin and C-peptide responses during an oral glucose tolerance test. The study showed differences in physiology between the groups. It did not establish that a large response itself causes the pancreas to deteriorate.

Other research used different sampling conditions. In a Brazilian cohort with C-peptide measured in about 3,800 young adults, nonfasting concentrations were associated with obesity and several cardiovascular and inflammatory risk factors. Those associations provide context for circulating C-peptide, but they do not establish a risk threshold for this one-hour glucose-challenge result.

Pregnancy and Later Childhood Metabolism

A study of 2,028 pregnancies included equal numbers of women with and without gestational diabetes. Among those with gestational diabetes, a pattern with a sharp C-peptide peak at 60 minutes was associated with greater insulin resistance and more fetal overgrowth. A slower response peaking at 120 minutes was associated with weaker insulin secretion. These groups were identified from fasting, one-hour, and two-hour measurements together.

In women without gestational diabetes, a high-response pattern was associated with preeclampsia. Preeclampsia is a pregnancy complication involving high blood pressure and signs of organ problems. This observational study did not establish that changing C-peptide prevents the condition or that one C-peptide result should determine pregnancy care.

The HAPO follow-up study also found that maternal fasting and one-hour C-peptide during pregnancy were associated with children's insulin concentrations and insulin resistance years later. Shared genes, maternal physiology, and the family environment can contribute to these relationships. The study did not show that maternal C-peptide caused the children's later metabolic differences.

Heart Disease and Survival

Most cardiovascular evidence concerns fasting or routine blood C-peptide, which differs from this timed glucose-challenge measurement. In a study of more than 5,000 adults without diabetes, higher fasting C-peptide was associated with cardiovascular and all-cause mortality. A meta-analysis also found associations with both outcomes.

Results for cardiovascular events are less consistent. A separate meta-analysis found an association in cross-sectional studies but no clear association in studies following people over time. A large retrospective study reported nonlinear relationships with other cardiovascular risk markers, but its association with subsequent cardiovascular events was no longer statistically clear after fuller adjustment. These findings do not establish that C-peptide itself protects or harms arteries, or that the one-hour result predicts your cardiovascular risk.

Low Insulin Production and Diabetes Complications

In people with insulin-treated diabetes, very limited remaining insulin production can accompany greater glucose variability and more severe hypoglycemia. Hypoglycemia means blood glucose has fallen too low. Much of this evidence comes from random, fasting, or mixed-meal C-peptide measurements, so it cannot be transferred directly into a one-hour glucose-test cutoff.

In 944 people with long-standing type 1 diabetes, higher residual C-peptide responses during a mixed-meal test were associated with fewer severe hypoglycemic events. The lowest detectable responses did not show the same advantage over undetectable results. Another mixed-meal study found that adults with higher residual production had better responses to experimental changes in glucose and spent more time within their glucose target range.

A separate study of fasting C-peptide in roughly 1,300 people with type 1 diabetes linked lower concentrations with poorer glucose control. Its complication analysis involved a smaller subgroup of 324 people. This supports the clinical relevance of residual secretion, while leaving uncertainty about how much an individual one-hour value predicts.

In insulin-treated type 2 diabetes, a small continuous glucose monitoring comparison found greater glucose variability and hypoglycemia among people with low random C-peptide. A larger study using fasting samples found that low C-peptide and GAD antibodies were each associated with severe hypoglycemia among people diagnosed with type 2 diabetes. These findings support assessing insulin deficiency when glucose is difficult to manage.

A 14-year study of more than 2,000 people with type 2 diabetes associated higher baseline fasting C-peptide with fewer new eye, kidney, and nerve complications, without a clear survival advantage. The different findings across diabetes populations reflect differences in insulin resistance, remaining secretion, glucose control, and kidney function. They do not define a single C-peptide level that is best for everyone.

Clarifying Your Diabetes Diagnosis

C-peptide can contribute to a review of an uncertain diabetes diagnosis. In one clinic, routine random serum C-peptide testing followed by further assessment led to reclassification of about 7% of adults who had carried a type 1 diagnosis for at least three years. Another UK center reported about 11% among adults whose diabetes began in adulthood. Most were reclassified as having type 2 diabetes or a single-gene form of diabetes. This was a diagnostic pathway using C-peptide, antibodies, and sometimes genetic testing; the one-hour glucose-challenge measurement was not the test evaluated.

When Results Can Be Misleading

• Glucose at the same moment: low glucose suppresses insulin secretion. Severe sustained hyperglycemia can also impair secretion temporarily, so a low result during a metabolic crisis may underestimate later recovery.
• Kidney function: reduced clearance can raise circulating C-peptide without a matching increase in insulin production.
• Sampling time and glucose dose: a late blood draw, an incomplete drink, vomiting, or a different glucose challenge can change the result. One time point cannot identify the shape or peak of the response.
• Different stimulation tests: fasting, random, glucose-drink, mixed-meal, and glucagon-stimulated results represent different conditions and are not automatically interchangeable. In one study of recent-onset type 1 diabetes, glucose-drink and mixed-meal results were similar on average.
• Medicines: drugs can change glucose, insulin release, or the speed at which the stomach empties. Injected insulin can indirectly lower C-peptide by lowering glucose, even though it contains none itself.
• Laboratory methods: immunoassays differ in calibration and in how they respond to interfering substances. Antibodies in a sample and cross-reaction with proinsulin can distort some results. High-dose biotin can interfere with some assay systems.
• Sample handling: damage to blood cells in the collection tube can falsely lower insulin. C-peptide is generally more resistant, though some assay platforms set limits on damaged samples. Unexpected findings need to be considered alongside collection and processing conditions.
• Preparation and short-term variation: recent carbohydrate restriction, acute illness, and unusual exercise can alter a glucose-challenge response. A change between two tests does not automatically mean beta cells have been lost.

Tracking Your Trend

Repeated measurements can help describe changes in insulin production when the challenge, laboratory method, and accompanying glucose measurements are comparable. In a pooled analysis of about 400 people recently diagnosed with type 1 diabetes, only about 5% maintained their starting mixed-meal C-peptide response four years later. The pace of decline varied, particularly with age, and these were mixed-meal results rather than isolated one-hour glucose-drink values.

The direction of change needs context. Falling C-peptide alongside rising glucose can raise concern about declining secretion. Falling C-peptide alongside improved glucose may reflect less need for compensatory insulin release. A stable or rising value can also reflect changes in kidney clearance or medication. The glucose and C-peptide pattern matters more than trying to move this number in one direction.